Compare RQI & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RQI | RARE |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | N/A | 2013 |
| Metric | RQI | RARE |
|---|---|---|
| Price | $13.07 | $23.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $59.95 |
| AVG Volume (30 Days) | 322.9K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 8.20% | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $673,000,000.00 |
| Revenue This Year | N/A | $13.12 |
| Revenue Next Year | N/A | $37.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.13 |
| 52 Week Low | $11.30 | $18.29 |
| 52 Week High | $13.39 | $40.17 |
| Indicator | RQI | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 60.11 | 54.67 |
| Support Level | $12.15 | $20.11 |
| Resistance Level | $13.38 | $25.70 |
| Average True Range (ATR) | 0.18 | 1.07 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 74.62 | 40.78 |
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.